Skip To Main Content
Ying-Xia Zhou on Muck Rack

Ying-Xia Zhou

As seen in: Frontiers in Immunology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ying-Xia

Contact Ying-Xia, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Frontiers | Gemcitabine-cisplatin chemotherapy plus anti-PD-L1 therapy reinvigorates antitumor immune response by reprogramming the intrahepatic cholangiocarcinoma microenvironment

|
By Shao-Wei Huang, Bo Shu, Bao-Ye Sun, Ying-Xia Zhou, Wei-Dong Dai
| Frontiers in Immunology
1 Introduction Intrahepatic cholangiocarcinoma (ICC) is a highly lethal malignancy accounting for up to 20% of all liver cancers (1), with continuously rising incidence and low 5-year survival rate (~9%) (2, 3). Surgical resection remains the only potential cure for ICC, whereas most patients are diagnosed at the advanced stage and only 20%-30% of patients are eligible for surgery (4).
Open in Who Shared Issue with article?
See all 1 articles